Guggenheim Maintains Buy Rating on Roivant Sciences
Guggenheim has reaffirmed its 'Buy' rating for Roivant Sciences, reflecting a continued positive outlook from the firm.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Guggenheim has reaffirmed its 'Buy' rating for Roivant Sciences, reflecting a continued positive outlook from the firm.
Immunovant, Inc. has filed an automatic shelf registration statement (S-3ASR) with the SEC, allowing for the potential future offering of securities.
An insider at Roivant Sciences Ltd. sold company shares valued at approximately $12.47 million, according to a recent SEC filing.
Truist Securities has raised its price target for Immunovant, Inc. from $30.00 to $33.00 while maintaining a 'Hold' rating on the stock.